Aequitron Medical acquires central nervous systems (CNS) sleep diagnostic range:
This article was originally published in Clinica
Electronic respiratory product manufacturer Aequitron Medical is to acquire CNS' sleep diagnostic business which has annual revenues of $7 million. The combined $6 million cash and debt transaction gives Aequitron rights to all CNS' sleep disorder diagnostic products as well as a product in development. It also gains distribution rights to CNS' Breathe Right nasal strips to professional healthcare markets. Production and staffing for the CNS products will move to Aequitron Medical's headquarters in Plymouth, Minnesota. CNS chairman and CEO Daniel Cohen says the company intends to concentrate on developing its core business - the Breathe Right product line.
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.